Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 8, Issue 1, 2003, Pages 61-69

  Prasad, Kailash ^a   Lee, Paul ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antioxidant reserve; Aspirin; Atherosclerosis; Chemiluminescence; Hypercholesterolemia; Malondialdehyde; White blood cells

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXYGEN RADICAL; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HYPERCHOLESTEROLEMIA; LEUKOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037346169     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840300800i109     Document Type: Article

References (43)

1. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of vitamin E. Am Heart J 125:958-973, 1993
2. Prasad K, Kalra J, Lee P. Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: Effects of probucol. Int J Angio 3:100-112, 1994
3. Steinberg D. Antioxidants; in the prevention of human atherosclerosis. Circulation 85:2338-2345, 1992
4. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99:1355-1362, 1999
5. Görog P, Kakkar VV. Increased uptake of monocyte-treated low density lipoproteins by aortic endothelium in vivo. Atherosclerosis 65:99-107, 1987
6. Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B, by platelets in vitro. N Engl J Med 302:6-10, 1980
7. Prisco D, Rogasi PG, Matucci M, et al. Age related changes in platelet lipid composition. Thromb Res 44:427-437, 1986
8. Shattil SJ, Anaya-Galindo R, Bennett J, et al. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55:636-643, 1975
9. Mosconi C, Colli S, Tremoli E, Galli C. Phosphatidylinositol (PI) and PI-associated arachidonate are elevated in platelet total membranes of type IIa hypercholesterolemic subjects. Atheroclerosis 72:129-134, 1988
10. Ruzicka T, Printz MP. Arachidonic acid metabolism in skin: A review. Rev Physiol Biochem Pharmaco. 100:121-160, 1984
11. Vansden Bosch H. Intracellular phospholipases A. Biochem Biophys Acta 604:191-246, 1980
12. ++ concentration and plasma cholesterol in untreated hypertensives. J Hypertension 5(suppl 5):S251-S254, 1987
13. Egan RW, Paxton J, Kuehl FA Jr. Mechanisms for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem 251:7329-7335, 1976
14. Marnett LJ, Wlodawer P, Samuelsson B. Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland, J Biol Chem 250:8510-8517, 1975
15. Panganamala RV, Sharma HM, Heikkila JC, et al. Role of hydroxyl radical scavengers dimethyl sulfoxide, alcohols and methional in the inhibition of prostaglandin biosynthesis. Prostaglandins 11:599-607, 1976
16. Murota I, Morita I, Suda N. The control of vascular endothelial cell injury. Ann NY Acad Sci 598:182-187, 1990
17. Henriksson P, Stamberger M, Diczfalusy U. Increased aortic thromboxane production in experimental atherosclerosis. Prostaglandins Leukot Med 29:71-77, 1987
18. Tremoli E, Folco G, Agradi E, Galli C. Platelet thromboxanes and serum cholesterol. Lancet 1:0107-108, 1979
19. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 345:1809-1817, 2001
20. Prasad K, Gupta JB, Kalra KaLra J, et al. Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol 28:375-385, 1996
21. Holman RS, McGill HC Jr, Strong JP, Greer JC. Technics for studying atheroclerotic lesions. Lab Invest 7:42-47, 1958
22. Kapoor R, Prasad K. Role of oxyradicals in cardiovascular depression and cellular injury in hemorrhagic shock and reinfusion: Effect of SOD and catalase. Circ Shock 43:79-94, 1994
23. Prasad K. Dietary flaxseed in prevention of hypercholesterolemic atherosclerosis. Atherosclerosis 132:69-76, 1997
24. Gornall AG, Bardwill CJ, David MM. Determination of serum proteins by means of biuret reaction. J Biol Chem 177:751-766, 1949
25. Prasad K, Mantha SV, Muir AD, Westcott ND. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis 136:367-375, 1998
26. Jelic-Ivanovic Z, Spasic S, Majkic-Singh N, Todorovic P. Effects of some anti-inflammatory drugs on 12 blood constituents: Protocol for the study of in vivo effects of drugs. Clin Chem 31:1141-1143, 1985
27. Zentella de Pina M, Saldana-Balmori Y, Hernandez-Tobia: A, Pina E. Nonsteroidal anti-inflammatory drugs lowe ethanol-mediated liver increase in lipids and thiobarbituric acid reactive substances. Alcohol Clin Exp Res 17:1228-1232, 1993
28. Sommariva D, Bonfiglioli D, Zanaboni L, Fasoli A. Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities. Int J Clin Pharmacol Ther Toxicol 19:112-116, 1981
29. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002
30. Fields M, Lewis CG, Bureau I. Aspirin reduces blood cholesterol in copper-deficient rats: A potential antioxidant agent? Metabolism 50:558-561, 2001
31. Manjula TS, Devi CS. Effect of aspirin on isoproterenol induced changes in lipid metabolism in rats. Indian J Med Res 98:30-33, 1993
32. Singh RB, Verma R, Mehta PJ, Rastogi SS. The effect of diet and aspirin on patient outcome after myocardial infarction. Nutrition 7:125-129, 1991
33. Gajdos M, Fedelesova V, Mongiellova V, et al. The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia. Bratisl Lek Listy 100:449-453, 1999
34. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: Evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728, 2000
35. Paul A, Calleja L, Camps J, et al. The continuous adminstration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68:457-465, 2000
36. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19:646-655, 1999
37. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 77:333-337, 1997
38. Oberle S, Polte T, Abate A, et al. Aspirin increases ferritin synthesis in endothelial cells: A novel antioxidant pathway. Circ Res 82:1016-1020, 1998
39. Mantha SV, Prasad M, Kalra J, Prasad K. Antioxidant enzymes in hypercholesterolemia and effects of vitamin E in rabbits. Atherosclerosis 101:135-144, 1993
40. Mantha SV, Kalra J, Prasad K. Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. Life Sci 58:503-509, 1996
41. Sacks T, Moldow CF, Craddock PR, et al. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes: An in vitro model of immune vascular damage. J Clin Invest 61:1161-1167, 1978
42. Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med 314:488-500, 1986
43. Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther 20:B18-B41, 1998